Ireland's Health Service Executive (HSE) has detected high-risk cannabinoids in vape products, vape juice, and edibles sold in shops and on the illicit market.
The discovery highlights a growing public health threat as synthetic substances enter the retail market, potentially exposing unsuspecting users to severe physical and mental health harms.
Analysis performed at the National Drug Treatment Centre Laboratory in Dublin was part of the HSE Drugs Early Warning System. This program identifies emerging drug threats to alert the public and medical professionals. Doctors said these substances can cause serious health complications.
Data from the monitoring program shows that 76 vape or vape-juice samples have been analyzed so far this year [1]. Of those samples, 41 contained CBD [2]. However, a significant portion of the tested products contained higher-risk compounds.
According to reports, 28 samples contained HHC or related compounds [1]. Other data indicates that 12 samples had cannabis or related compounds [2]. The presence of these substances in products sold in shops suggests that illicit materials are bypassing standard retail safeguards.
The HSE continues to monitor the market to identify the scale of the contamination. The agency said the early warning system is essential for tracking how new synthetic cannabinoids move through the country—both in legal retail settings and through underground networks.
Public health officials are urging consumers to be cautious of the ingredients in vape products and edibles. Because these products are often unregulated or mislabeled, users may unknowingly ingest potent synthetic cannabinoids that differ significantly from legal CBD products.
“High-risk cannabinoids detected in vape products, vape juice, and edibles sold in shops.”
The detection of HHC and other cannabis-related compounds in retail environments suggests a failure in supply chain regulation. By utilizing the Drugs Early Warning System, the HSE is attempting to bridge the gap between the rapid emergence of synthetic cannabinoids and the slower pace of legislative bans, aiming to prevent a surge in emergency room admissions related to synthetic drug toxicity.
